{"DataElement":{"publicId":"2688923","version":"2","preferredName":"Plasma Cell Disorder Classification Type","preferredDefinition":"A description of plasma cell disorder classification.","longName":"PLSM_CL_DZ_CLS_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2688899","version":"1","preferredName":"Plasma Cell Disorder Classification","preferredDefinition":"Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20)_Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"PLSM_CL_DZ_CLS","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2685344","version":"1","preferredName":"Plasma Cell Diseases and Disorders","preferredDefinition":"Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20):A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C12486:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell","conceptCode":"C12486","definition":"A fully mature B-Cell that produces a specific antibody.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BABCF9E-9CB5-6EE1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4AF4A9-1215-4906-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2688911","version":"1.1","preferredName":"Plasma Cell Disorder Type","preferredDefinition":"Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20)_Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Something distinguishable as an identifiable class based on common qualities.","longName":"PLSM_DZ_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Light chain deposition disease","valueDescription":"Light Chain Deposition Disease","ValueMeaning":{"publicId":"3928712","version":"1","preferredName":"Light Chain Deposition Disease","longName":"3928712","preferredDefinition":"A condition in which plasma cells secrete immunoglobulin light chains of only one type, kappa or lambda. Light chain deposition disease is often associated with multiple myeloma or lymphoproliferative disease, but as many as 50% of patients have no evidence of neoplastic plasma cell proliferation. Light chains excreted in the urine are known as Bence Jones protein. Amyloidosis and severe renal failure occur more frequently than in multiple myeloma. Also known as Bence Jones myeloma. L-chain disease, L-chain myeloma, and LCDD. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Light Chain Deposition Disease","conceptCode":"C7727","definition":"A condition in which plasma cells secrete immunoglobulin light chains of only one type, kappa or lambda. Light chain deposition disease is often associated with multiple myeloma or lymphoproliferative disease, but as many as 50% of patients have no evidence of neoplastic plasma cell proliferation. Light chains excreted in the urine are known as Bence Jones protein. Amyloidosis and severe renal failure occur more frequently than in multiple myeloma. Also known as Bence Jones myeloma. L-chain disease, L-chain myeloma, and LCDD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C7BE5-6B3B-5A74-E040-BB89AD431D30","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C7BE5-6B54-5A74-E040-BB89AD431D30","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Osteosclerotic myeloma / POEMS syndrome","valueDescription":"Osteosclerotic Myeloma","ValueMeaning":{"publicId":"3928714","version":"1","preferredName":"Osteosclerotic Myeloma","longName":"3928714","preferredDefinition":"A plasma cell neoplasm associated with osteosclerotic and fibrotic changes in the bone trabeculae.  Often, the lymph nodes show changes resembling the plasma cell variant of Castleman disease.  It is often part of POEMS syndrome which is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteosclerotic Multiple Myeloma","conceptCode":"C7765","definition":"Multiple myeloma associated with osteosclerotic and fibrotic changes in the bone trabeculae.  Often, the lymph nodes show changes resembling the plasma cell variant of Castleman disease.  It is often part of POEMS syndrome which is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C7BE5-6B61-5A74-E040-BB89AD431D30","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C7BE5-6B7A-5A74-E040-BB89AD431D30","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Multiple myeloma-IgD","valueDescription":"Multiple Myeloma-IgD","ValueMeaning":{"publicId":"2688918","version":"1","preferredName":"Multiple Myeloma-IgD","longName":"2688918","preferredDefinition":"The heavy chain, IgD, of the immunoglobulin is defective.  This multiple myeloma subtype is very rare (~1%).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IgD Multiple Myeloma","conceptCode":"C70607","definition":"A finding of multiple myeloma in which the heavy chain of the immunoglobulin D is defective. This multiple myeloma subtype is very rare (~1%).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-20E7-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C7BE5-6BA2-5A74-E040-BB89AD431D30","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Multiple myeloma-IgE","valueDescription":"Multiple Myeloma-IgE","ValueMeaning":{"publicId":"2688917","version":"1","preferredName":"Multiple Myeloma-IgE","longName":"2688917","preferredDefinition":"The heavy chain, IgE, of the immunoglobulin is defective.  This multiple myeloma subtype is extremely rare.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IgE Multiple Myeloma","conceptCode":"C70608","definition":"A finding of multiple myeloma in which the heavy chain of the immunoglobulin E is defective. This multiple myeloma subtype is extremely rare.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-20C0-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C7BE5-6BB6-5A74-E040-BB89AD431D30","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Multiple myeloma-IgG","valueDescription":"Multiple Myeloma-IgG","ValueMeaning":{"publicId":"2688916","version":"1","preferredName":"Multiple Myeloma-IgG","longName":"2688916","preferredDefinition":"The heavy chain, IgG, of the immunoglobulin is defective.  This is the most common type of multiple myeloma (>50%).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IgG Multiple Myeloma","conceptCode":"C70609","definition":"A finding of multiple myeloma in which the heavy chain of the immunoglobulin G is defective. This is the most common type of multiple myeloma (>50%).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-2099-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C7BE5-6BCA-5A74-E040-BB89AD431D30","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Multiple myeloma-IgM (not Waldenstrom macroglobulinemia)","valueDescription":"Multiple Myeloma-IgM (not Waldenstrom Macroglobulinemia)","ValueMeaning":{"publicId":"2688915","version":"1","preferredName":"Multiple Myeloma-IgM (not Waldenstrom Macroglobulinemia)","longName":"2688915","preferredDefinition":"The heavy chain, IgM, of the immunoglobulin is defective.  This form is often associated with other plasma cell disorders. IgM is also defective in Waldenstrom, but it is a different disease from multiple myeloma IgM.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IgM Multiple Myeloma (not Waldenstrom Macroglobulinemia)","conceptCode":"C70610","definition":"A finding of multiple myeloma in which the heavy chain of the immunoglobulin M is defective. This finding is seen in other lymphocytic/plasmacytic disorders as well, including Waldenstrom macroglobulinemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-2072-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C7BE5-6BDE-5A74-E040-BB89AD431D30","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Multiple myeloma-light chain only","valueDescription":"Multiple Myeloma-Light Chain Only","ValueMeaning":{"publicId":"2688914","version":"1","preferredName":"Multiple Myeloma-Light Chain Only","longName":"2688914","preferredDefinition":"Only the light chain (kappa or lambda) of the immunoglobulin is defective.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Light Chain Multiple Myeloma","conceptCode":"C70605","definition":"A finding of multiple myeloma in which  the light chain (kappa or lambda) of the immunoglobulin is defective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-204B-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C7BE5-6BF2-5A74-E040-BB89AD431D30","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Other plasma cell disorder","valueDescription":"Other Plasma Cell Diseases and Disorders","ValueMeaning":{"publicId":"2688912","version":"1","preferredName":"Other Plasma Cell Diseases and Disorders","longName":"2688912","preferredDefinition":"Not otherwise specified.: Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20): A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Plasma Cell","conceptCode":"C12486","definition":"A fully mature B-Cell that produces a specific antibody.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-1FD3-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C7BE5-6C06-5A74-E040-BB89AD431D30","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Amyloidosis","valueDescription":"Amyloidosis","ValueMeaning":{"publicId":"3322390","version":"1","preferredName":"Amyloidosis","longName":"3322390","preferredDefinition":"A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BC68-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C7BE5-6C10-5A74-E040-BB89AD431D30","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Solitary plasmacytoma (no evidence of myeloma)","valueDescription":"Solitary Plasmacytoma","ValueMeaning":{"publicId":"2579743","version":"1","preferredName":"Solitary Plasmacytoma","longName":"2579743","preferredDefinition":"A localized clonal (malignant) plasma cell infiltrate either in the bone or in another anatomic site without peripheral blood involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solitary Plasmacytoma","conceptCode":"C6932","definition":"A localized malignant neoplasm that arises in the bony skeleton or soft tissue. It is composed of clonal (malignant) plasma cells forming a tumor mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-048C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-15","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-15","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C0471-0996-638E-E040-BB89AD436B99","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Plasma cell leukemia","valueDescription":"Plasma Cell Leukemia","ValueMeaning":{"publicId":"2579742","version":"1","preferredName":"Plasma Cell Leukemia","longName":"2579742","preferredDefinition":"An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell Leukemia","conceptCode":"C3180","definition":"An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-048B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-15","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-15","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C0471-09A0-638E-E040-BB89AD436B99","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Multiple myeloma-non-secretory","valueDescription":"Non-Secretory Myeloma","ValueMeaning":{"publicId":"2688913","version":"1","preferredName":"Non-Secretory Myeloma","longName":"2688913","preferredDefinition":"A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Secretory Multiple Myeloma","conceptCode":"C4734","definition":"A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-2024-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97C0471-09AA-638E-E040-BB89AD436B99","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Multiple myeloma-IgA","valueDescription":"Multiple Myeloma-IgA","ValueMeaning":{"publicId":"2688919","version":"1","preferredName":"Multiple Myeloma-IgA","longName":"2688919","preferredDefinition":"The heavy chain, IgA, of the immunoglobulin is defective.  This is the second most common type of multiple myeloma (~20%).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IgA Multiple Myeloma","conceptCode":"C70606","definition":"A finding of multiple myeloma in which the heavy chain of the immunoglobulin A is defective. This is the second most common type of multiple myeloma (~20%).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C44B0-210E-5F6E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC1971D8-E5A9-0487-E040-BB89AD43782C","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-26","modifiedBy":"ONEDATA","dateModified":"2013-11-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2688910","version":"1","preferredName":"Plasma Cell Diseases and Disorders Type","preferredDefinition":"Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20):A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.:Type; a subdivision of a particular kind of thing.","longName":"C12486:C2991:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell","conceptCode":"C12486","definition":"A fully mature B-Cell that produces a specific antibody.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C4425-8575-5F14-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ONEDATA","dateModified":"2007-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C0471-0975-638E-E040-BB89AD436B99","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PreTed_prime_dis_hct_mye_pcd_class","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"pre_ted_who_plasma_cell","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_ICT_mye_pcd_class","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_PCD_mye_pcd_class","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the multiple myeloma/plasma cell disorder classification:","type":"Alternate Question Text","description":"Specify the multiple myeloma/plasma cell disorder classification:","url":null,"context":"NHLBI"},{"name":"What was the classification o","type":"Preferred Question Text","description":"What was the classification of plasma cell disorders?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2688923","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.value(ANY=>CD).code","url":null,"context":"NHLBI"},{"name":"Specify the multiple myeloma/plasma cell disorder (PCD) classification","type":"Application Standard Question Text","description":"Specify the multiple myeloma/plasma cell disorder (PCD) classification","url":null,"context":"NHLBI"},{"name":"What is the diagnosis?","type":"Alternate Question Text","description":"What is the diagnosis?","url":null,"context":"NHLBI"},{"name":"Specify the multiple myeloma/plasma cell disorder classification","type":"Alternate Question Text","description":"Specify the multiple myeloma/plasma cell disorder classification","url":null,"context":"NHLBI"},{"name":"Specify the multiple myeloma/plasma cell disorder (PCD) classification","type":"Alternate Question Text","description":"Specify the multiple myeloma/plasma cell disorder (PCD) classification","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C7BE5-6C1A-5A74-E040-BB89AD431D30","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":".Added AQT 2014-02-14 SLS.7/9/14mn-added aqt w/out colon. Added human readable def. System generated def displayed as alt def. No version needed. AK 11/17/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}